Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 4/20 | 0.65 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
| ▸ | HTR2B | P41595 | 1/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.49 |
| ▸ | IDO1 | P14902 | 1/20 | 0.48 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.44 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.44 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7868650 | 1.00 | FFAR1 (0.65) | FFAR1LPAR2HTR2AHTR2CSLC6A4 | |
| SCHEMBL23116570 | 1.00 | FFAR1 (0.65) | FFAR1LPAR2HTR2AHTR2CSLC6A4 | |
| SCHEMBL10288305 | 1.00 | FFAR1 (0.65) | FFAR1LPAR2HTR2AHTR2CSLC6A4 | |
| SCHEMBL21501054 | 1.00 | FFAR1 (0.65) | FFAR1LPAR2HTR2AHTR2CSLC6A4 | |
| SCHEMBL16232156 | 0.86 | FFAR1 (0.50) | FFAR1LPAR2HTR2AHTR2CSLC6A4 | |
| SCHEMBL29303274 | 0.85 | HTR2A (0.51) | FFAR1LPAR2HTR2AHTR2CSLC6A4 | |
| SCHEMBL12087471 | 0.83 | FFAR1 (0.65) | FFAR1IDO1GPR88ALDH1A1LMNA | |
| SCHEMBL7002531 | 0.82 | FFAR1 (0.56) | FFAR1IDO1HDAC4ALDH1A1LMNA | |
| SCHEMBL7002528 | 0.82 | FFAR1 (0.56) | FFAR1IDO1HDAC4ALDH1A1LMNA | |
| SCHEMBL1817810 | 0.81 | ROCK2 (0.49) | FFAR1LPAR2HTR2AHTR2CSLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2742029-B1 | N-(BENZIMIMDAZOL-2-YL)-CYCLOPROPANE CARBOXAMIDES AS LYSOPHOSPHATIDIC ACID ANTAGONISTS | MERCK PATENT GMBH (DE) | 2016-10-05 | — | — | EP | claimed |
| US-8912202-B2 | N-(benzimimdazol-2-yl)-cyclopropane carboxamides as lysophosphatidic acid antagonists | MERCK PATENT GMBH (DE) | 2014-12-16 | — | — | US | claimed |
| US-20140228378-A1 | N-(Benzimimdazol-2-yl)-Cyclopropane Carboxamides as Lysophosphatidic Acid Antagonists | MERCK PATENT GMBH (DE) | 2014-08-14 | — | — | US | claimed |
| EP-2742029-A1 | N-(BENZIMIMDAZOL-2-YL)-CYCLOPROPANE CARBOXAMIDES AS LYSOPHOSPHATIDIC ACID ANTAGONISTS | Merck Patent GmbH (DE) | 2014-06-18 | — | — | EP | claimed |
| WO-2013020622-A1 | N-(BENZIMIMDAZOL-2-YL)-CYCLOPROPANE CARBOXAMIDES AS LYSOPHOSPHATIDIC ACID ANTAGONISTS | MERCK PATENT GMBH (DE) | 2013-02-14 | — | — | WO | claimed |
| US-20230357214-A1 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | PHENEX PHARMACEUTICALS AKTIENGESELLSCHAFT (DE) | 2023-11-09 | — | — | US | disclosed |
| EP-3814331-B9 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | ORSOBIO INC (US) | 2023-08-09 | — | — | EP | disclosed |
| US-20210147398-A1 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | PHENEX-FXR GMBH (DE) | 2021-05-20 | — | — | US | disclosed |
| WO-2019204477-A1 | PD(II)-CATALYZED ENANTIOSELECTIVE C-H ARYLATION OF FREE CARBOXYLIC ACIDS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2019-10-24 | — | — | WO | disclosed |
| EP-2742029-B1 | N-(BENZIMIMDAZOL-2-YL)-CYCLOPROPANE CARBOXAMIDES AS LYSOPHOSPHATIDIC ACID ANTAGONISTS | MERCK PATENT GMBH (DE) | 2016-10-05 | — | — | EP | disclosed |
| US-20150322052-A1 | ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS | RAQUALIA PHARMA INC (JP) | 2015-11-12 | — | — | US | disclosed |
| US-20150322052-A1 | ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS | RAQUALIA PHARMA INC (JP) | 2015-11-12 | — | — | US | disclosed |
| US-20100190230-A1 | Potent and Selective Neuronal Nitric Oxide Synthase Inhibitors with Improved Membrane Permeability | NORTHWESTERN UNIVERSITY | 2010-07-29 | — | — | US | disclosed |
| US-7714136-B2 | Tetrahydropyridothiophenes | 4SC AG (DE) | 2010-05-11 | — | — | US | disclosed |
| US-20090258873-A1 | Novel tetrahydropyridothiophenes | PEKARI KLAUS | 2009-10-15 | — | — | US | disclosed |
| US-20080206258-A1 | Novel Tetrahydropyridothiophenes | NYCOMED GMBH (DE) | 2008-08-28 | — | — | US | disclosed |
| US-20060030718-A1 | Cobalt-based catalysts for the cyclization of alkenes | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2006-02-09 | — | — | US | disclosed |
| EP-0996621-B1 | TRIAZOLO[4,5-d]PYRIMIDINE DERIVATIVES AS ANTI-THROMBOTIC AGENTS | ASTRAZENECA AB (SE) | 2003-10-01 | — | — | EP | disclosed |
| EP-0996621-A1 | NOVEL COMPOUNDS | Astra Pharmaceuticals Limited (GB) | 2000-05-03 | — | — | EP | disclosed |
| WO-1999005143-A1 | NOVEL COMPOUNDS | ASTRA PHARMACEUTICALS LTD. (GB) | 1999-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140228378-A1 | N-(Benzimimdazol-2-yl)-Cyclopropane Carboxamides as Lysophosphatidic Acid Antagonists | LPAR5, LPAR2, LPAR1 | FFAR1 85/4885LPAR2 2/4885HTR2A 2304/4885 |
| US-20060030718-A1 | Cobalt-based catalysts for the cyclization of alkenes | PPOX, HCCS, ICOSLG | FFAR1 4727/4885LPAR2 3703/4885HTR2A 4578/4885 |
| US-20150322052-A1 | ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS | CACNA1I, CACNA1G, CACNA1H | FFAR1 1439/4885LPAR2 1998/4885HTR2A 1507/4885 |
| US-20080206258-A1 | Novel Tetrahydropyridothiophenes | BAX, BCL2, CCAR2 | FFAR1 3294/4885LPAR2 3277/4885HTR2A 3366/4885 |
| US-20100190230-A1 | Potent and Selective Neuronal Nitric Oxide Synthase Inhibitors with Improved Membrane Permeability | NOS1, NOS2, NOS3 | FFAR1 971/4885LPAR2 1356/4885HTR2A 1266/4885 |
| US-20210147398-A1 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | NR1H2, NR1H3, NR1H4 | FFAR1 63/4885LPAR2 54/4885HTR2A 752/4885 |
| US-20230357214-A1 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | NR1H2, NR1H3, NR1H4 | FFAR1 63/4885LPAR2 54/4885HTR2A 752/4885 |
| US-20090258873-A1 | Novel tetrahydropyridothiophenes | BAX, BCL2, CCAR2 | FFAR1 3410/4885LPAR2 3374/4885HTR2A 3436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.